{"id":10519,"date":"2010-06-01T16:32:24","date_gmt":"2010-06-01T16:32:24","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10519"},"modified":"2010-06-01T16:32:24","modified_gmt":"2010-06-01T16:32:24","slug":"raltegravir-dose-adjustment-not-required-for-patients-on-dialysis","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10519","title":{"rendered":"Raltegravir dose adjustment not required for patients on dialysis"},"content":{"rendered":"<p><strong>www.hiv-druginteractions.org<\/strong><\/p>\n<p>The effect of haemodialysis on raltegravir clearance was evaluated in two anuric end stage renal disease HIV-positive patients.<\/p>\n<p>Predialyzer (C_in) and postdialyzer (C_out) blood samples were collected at the beginning and end of a single 4 h dialysis session and the haemodialysis extraction ratio (ER) was calculated using (C_in &#8211; C_out)\/C_in.\u00a0 Raltegravir dialysis clearance (CLd) in terms of plasma was calculated using ER x Qp, where Qp is plasma flow through the dialyzer.<\/p>\n<p>At the end of the session, raltegravir concentrations decreased by 68% in patient 1 and by 45% in patient 2. However, ER and CLd were only 5.5% and 9.1 mL\/min in patient 1, and 9.5% and 19.1 mL\/min in patient 2, respectively.Both patients maintained raltegravir concentrations higher than 15 ng\/mL at the end of the dialysis session.<\/p>\n<h2>comment<\/h2>\n<p> <strong>These results show minimal removal of raltegravir by haemodialysis and dosage adjustments of raltegravir may not be required.<\/strong><\/p>\n<p>Ref: Molto J et al. Effect of hemodialysis on raltegravir clearance in HIV-infected patients with end stage renal disease.11th PK Workshop, 2010. Abstract 7.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>www.hiv-druginteractions.org The effect of haemodialysis on raltegravir clearance was evaluated in two anuric end stage renal disease HIV-positive patients. Predialyzer (C_in) and postdialyzer (C_out) blood samples were collected at the beginning and end of a single 4 h dialysis session &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[134],"class_list":["post-10519","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-pk-workshop-11th-2010"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10519"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10519\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}